The Company signed a non-binding MOU with shareholders of Colugo. Colugo’s customer include the Israel Defense Forces, national first responders organizations and commercial companies Raanana, Israel, March 24, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the signing of a non-binding Memorandum of Understanding (“MOU”) with shareholders of Colugo Systems Ltd. (“Co ...

Core Insights - Polyrizon Ltd. has signed an agreement with a leading global preclinical Contract Research Organization (CRO) to advance its clinical development program for intranasal solutions [1][2] Group 1: Agreement and Development Program - The agreement is part of Polyrizon's efforts to enhance its clinical development, which includes GMP production of clinical trial material and a successful FDA pre-submission meeting [2][5] - The CRO will conduct preclinical biocompatibility studies in accordance with ISO 10993 standards and GLP requirements, expected to start in Q2 2026 [3][4] - These studies are crucial for supporting regulatory submissions and ensuring product safety before human trials [4][5] Group 2: Technology and Product Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [6] - The proprietary Capture and Contain TM hydrogel technology aims to function as a "biological mask" in the nasal cavity [6] - The company is also developing the Trap and Target ™ technology for nasal delivery of active pharmaceutical ingredients, which is in earlier preclinical stages [6]

Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate. This milestone follows the Company’s previously announced manufacturing agreement with Eurofins CDMO AmatsiAquitaine S.A.S, a leading global GMP CDMO, estab ...

Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. T ...

Core Insights - Polyrizon Ltd. has rebranded its lead intranasal allergy product to NASARIX™, marking a significant step towards potential commercialization [1] - The global market for allergic rhinitis treatments is projected to grow from approximately USD 13.08 billion in 2025 to USD 18.81 billion by 2035, with a CAGR of 3.7% [1] - NASARIX™ utilizes a unique hydrogel technology to create a barrier that physically traps allergens, offering a drug-free alternative to traditional allergy treatments [1] Company Overview - Polyrizon is a pre-clinical-stage biotechnology company focused on developing intranasal protective solutions [1] - The company is currently conducting a human factors and usability study to validate the product's instructions and user experience, aligning with FDA guidance [1] - Polyrizon plans to initiate clinical trials for NASARIX™ in Q3 2026, positioning it as a medical device for a more streamlined approval process [1] Industry Context - Allergic rhinitis affects an estimated 10–30% of the global population, with over 60 million people in the U.S. impacted annually [1] - The demand for intranasal therapies and non-sedating alternatives is driving market growth, as most current treatments are reactive rather than preventive [1] - NASARIX™ aims to fill a gap in the market by providing a proactive, user-friendly solution for allergy sufferers [1]

Core Viewpoint - Polyrizon Ltd. has signed a non-binding Memorandum of Understanding (MOU) to acquire a 51% stake in Arrow Aviation, a high-growth private aviation company, for approximately $5.8 million, marking a strategic entry into the private aviation sector [1][3]. Company Overview - Polyrizon is a pre-clinical-stage biotechnology company focused on developing intranasal protective solutions, including innovative medical device hydrogels delivered as nasal sprays [5]. - Arrow Aviation, with annual unaudited revenues of approximately $19 million and adjusted EBITDA of around $3 million, provides private aviation services, operating a fleet of executive jets and catering to both leisure and business clients [2]. Strategic Rationale - The acquisition is seen as a diversification opportunity for Polyrizon, allowing the company to leverage its financial position to enter the growing private aviation market, projected to reach $41.38 billion by 2030 [3]. - The proposed transaction includes arrangements for a third-party transfer of a Hawker 800 aircraft valued at $3.5 million and the forgiveness of outstanding debts by existing Arrow Aviation shareholders in exchange for convertible notes from Polyrizon [3]. Transaction Details - A definitive agreement is expected to be signed within 30 days of the MOU, subject to due diligence, with the closing of the acquisition anticipated to follow customary closing conditions [4].

Core Viewpoint - Clearmind Medicine Inc. has entered into a development agreement with Polyrizon Ltd. to enhance the bioavailability and clinical advancement of its lead compound MEAI for addiction-related and other CNS disorders [1][2][3] Group 1: Collaboration Details - The agreement involves the application of Polyrizon's proprietary intranasal hydrogel technology to develop an optimized formulation of Clearmind's MEAI [2][3] - The collaboration aims to leverage the advantages of intranasal delivery for CNS-targeted therapeutics, which include enhanced nasal residence time, targeted delivery, and bypassing first-pass metabolism [3][5] Group 2: Company Insights - Clearmind is focused on discovering and developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including addiction and mental health disorders [1][6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [6] Group 3: Technology Overview - Polyrizon specializes in developing innovative medical device hydrogels for nasal delivery, which can provide a barrier against viruses and allergens [7] - Their proprietary Capture and Contain™ hydrogel technology aims to improve bioadhesion and retention at the nasal deposition site for drug delivery [7]

Core Viewpoint - Polyrizon Ltd. has entered into a development agreement with Clearmind Medicine Inc. to leverage Polyrizon's intranasal delivery platform for the clinical development of Clearmind's drug candidate MEAI, aimed at treating addiction-related and other CNS conditions [1][2][3] Group 1: Collaboration Details - The collaboration aims to advance an intranasal formulation of MEAI to support Clearmind's future clinical development programs [2] - Polyrizon's proprietary intranasal technology is designed to enable targeted and efficient delivery of drugs, potentially offering significant value in Clearmind's clinical pathway [3] Group 2: Polyrizon's Technology - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The company's Capture and Contain TM hydrogel technology is designed to enhance bioadhesion and prolong retention at the nasal site for drug delivery [4][6] Group 3: Clearmind's Focus - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address underserved health issues, including alcohol use disorder [7] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [8]

Core Viewpoint - Polyrizon Ltd. has signed a non-binding Memorandum of Understanding (MOU) to acquire a 51% stake in Arrow Aviation, a high-growth private aviation company, for approximately $5.8 million, marking a strategic entry into the private aviation sector [1][3]. Company Overview - Polyrizon is a pre-clinical-stage biotechnology company focused on developing intranasal protective solutions, including innovative medical device hydrogels delivered as nasal sprays [5]. - Arrow Aviation is a leading provider of private aviation services with annual unaudited revenues of approximately $19 million and adjusted EBITDA of around $3 million, operating a fleet of executive jets and offering tailored VIP flights [2]. Strategic Expansion - The acquisition of Arrow Aviation is seen as a diversification opportunity for Polyrizon, allowing the company to leverage its financial position to enter a private aviation market projected to grow to $41.38 billion by 2030 [3]. - The proposed transaction includes arrangements for a Hawker 800 aircraft valued at $3.5 million and the forgiveness of outstanding shareholder debts by existing Arrow Aviation shareholders in exchange for convertible notes from Polyrizon [3]. Transaction Timeline - A definitive agreement is expected to be signed within 30 days of the MOU, subject to due diligence, with the closing of the acquisition anticipated to follow customary closing conditions [4].

Core Insights - Polyrizon Ltd. has initiated a key usability study for its lead product candidate, NASARIX™, aimed at confirming alignment with FDA requirements and supporting clinical development [1][2] Group 1: Product Development - NASARIX™ is an innovative intranasal allergy blocker designed for broad consumer use, representing a significant advancement in Polyrizon's development roadmap [1][2] - The usability study is intended to de-risk downstream regulatory review and facilitate a streamlined path toward clinical trials [2][3] Group 2: Regulatory Milestones - Successful completion of the usability program will provide essential regulatory evidence for NASARIX™'s readiness for clinical evaluation, with trials expected to commence in Q3 2026 [3][4] - The study underscores the company's commitment to FDA-aligned development, patient safety, and user-centered solutions [4] Group 3: Company Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The proprietary Capture and Contain™ hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development focused on enhancing bioadhesion and retention [4]